Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Description and therapy of palmoplantar pustular psoriasis under IL-17A or dual IL-17A/F inhibition.

Journal of autoimmunity·2026
Same author

Combined immunosuppressive therapy in systemic sclerosis-associated interstitial lung disease: Phenotypes matter.

Autoimmunity reviews·2026
Same author

Real-world clinical experience with upadacitinib in a cohort of Italian patients with axial spondyloarthritis.

Frontiers in pharmacology·2026
Same author

Modulation of proinflammatory but not regulatory cytokines by in vitro JAK inhibition in peripheral blood B-cells of patients with psoriatic arthritis.

Journal of dermatological science·2026
Same author

Achievement and Maintenance of Remission with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in Italy: 1-Year Data from UPHOLD, a Prospective Real-World Observational Study.

Rheumatology and therapy·2026
Same author

Natural language processing to intercept rheumatoid and psoriatic arthritis from clinical notes in the Emergency Department.

Therapeutic advances in musculoskeletal disease·2026

関連する実験動画

Updated: Jun 2, 2026

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

プライマリー胆道硬化症 (Primary biliary cirrhosis) というものです.

Carlo Selmi1, Christopher L Bowlus, M Eric Gershwin

  • 1Department of Translational Medicine, IRCCS-Istituto Clinico Humanitas, University of Milan, Milan, Italy.

Lancet (London, England)
|May 3, 2011
PubMed
まとめ
この要約は機械生成です。

主要胆管硬化症 (PBC) は,抗ミトコンドリア抗体 (AMA) によって診断される自己免疫性肝疾患です. ウルソデオキシコール酸による治療は予後を改善しますが,反応しない患者には代替療法が必要です.

関連する実験動画

Last Updated: Jun 2, 2026

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

科学分野:

  • 肝臓病理学 肝臓病理学
  • 自己免疫学とは,自己免疫学です.
  • 胃腸内科 胃腸内科

背景:

  • 主要胆管硬化症 (PBC) は,肝臓内胆管の破壊によって特徴づけられる慢性的な自己免疫性肝疾患です.
  • 遺伝的傾向と環境要因 (化学物質,感染症) がPBCの病原化に寄与する証拠があります.
  • 発症率の増加は,病気の発生率の真の増加ではなく,診断検査の強化に関連している可能性があります.

研究 の 目的:

  • 主要胆硬化症 (PBC) の病理生理学,診断,および管理に関する現在の理解を要約します.
  • 診断における抗ミトコンドリア抗体 (AMA) の役割を強調する.
  • ウルソデオキシコール酸 (UDCA) 治療の効果と代替治療の必要性について議論する.

主な方法:

  • 主要胆硬化症に関する既存の文献のレビュー.
  • 抗ミトコンドリア抗体 (AMA) を含む診断マーカーの分析.
  • ウルソデオキシコール酸 (UDCA) による治療結果の評価.

主要な成果:

  • 抗ミトコンドリア抗体 (Antimitochondrial antibodies, AMA) は,ほとんどの一次性胆管硬化症 (PBC) 症例の診断的特徴であり,早期発見を可能にします.
  • ウルソデオキシコール酸 (UDCA) は主な治療法であり,疾患の進行を遅らせ,予後を改善します.
  • 患者のサブセットはUDCAに対する不十分な反応を示しており,代替治療戦略の探索が必要である.

結論:

  • 主要胆管硬化症 (PBC) は,多因子の病因性を持つ複雑な自己免疫性肝疾患である.
  • 早期診断とUDCA治療は,患者のアウトカムを大幅に改善しています.
  • 代替治療法に関するさらなる研究は,現在の治療法に反応しない患者にとって極めて重要です.